- Open
- 600.00
- High
- 665.00
- Low
- 600.00
- Close
- 660.00
- Change
- +47.00 (7.69%)
- Volume
- 291,815
| 8 Jul 2026 | 17:57:49 | Holding(s) in Company |
| 1 Jul 2026 | 07:00:02 | Total Voting Rights |
| 22 Jun 2026 | 10:10:05 | Admission to Trading |
| 17 Jun 2026 | 08:10:18 | Admission to trading application |
| 2 Jun 2026 | 07:00:05 | OXB Capital Markets Event |
| 30 Mar 2026 | Annual financial and audit reports | |
| 28 Apr 2025 | Annual financial and audit reports | |
| 30 Apr 2024 | Annual Report and accounts 31-Dec-2023 |
Oxford BioMedica is a company that specializes in gene and cell therapy, and is a leader in the research, development, and bioprocessing of lentiviral and cell therapy.
| 8 Jul 2026 | 17:57:49 | Holding(s) in Company |
| 1 Jul 2026 | 07:00:02 | Total Voting Rights |
| 22 Jun 2026 | 10:10:05 | Admission to Trading |
| 17 Jun 2026 | 08:10:18 | Admission to trading application |
| 2 Jun 2026 | 07:00:05 | OXB Capital Markets Event |
| 30 Mar 2026 | Annual financial and audit reports | |
| 28 Apr 2025 | Annual financial and audit reports | |
| 30 Apr 2024 | Annual Report and accounts 31-Dec-2023 |
Oxford BioMedica is a company that specializes in gene and cell therapy, and is a leader in the research, development, and bioprocessing of lentiviral and cell therapy.
| 2 Jun 2026 |
| Oxford Biomedica sets £500m revenue target as capital markets day shores investor confidence |
| 24 Feb 2026 | Oxford Biomedica trading update ignored as bid deadline looms |
| 2 Jun 2026 |
| Oxford Biomedica sets £500m revenue target as capital markets day shores investor confidence |
| 24 Feb 2026 | Oxford Biomedica trading update ignored as bid deadline looms |
